Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Cosentyx | secukinumab | Hidradenitis suppurativa | Suspended | |||
| Leqembi | lecanemab | Alzheimer’s disease | Pending | |||
| Alecensaro | alectinib | ALK-positive NSCLC | Active | |||
| Adcetris | Brentuximab vedotin | Hodgkin lymphoma | Active | |||
| N/A | enzalutamide | Genito-urinary cancer (prostate cancer) | Open for Stakeholder Input | |||
| Balversa | erdafitinib | locally advanced unresectable or metastatic urothelial carcinoma (UC) | Pending | |||
| Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Active | |||
| Elrexfio | elranatamab | Relapsed or refractory multiple myeloma | Active | |||
| Orgovyx | relugolix | Advanced prostate cancer | Active | |||
| Keytruda | pembrolizumab | Biliary tract carcinoma | Active |
Last Updated : May 9, 2024